Showing 4471-4480 of 5627 results for "".
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- EssilorLuxottica Signs Agreement to Acquire Walmanin the UShttps://modernod.com/news/essilorluxottica-signs-agreement-to-acquire-walmanin-the-us/2479016/EssilorLuxottica has entered into an agreement to acquire US-based lab network Walman. Terms of the deal were not disclosed. EssilorLuxottica’s investment in Walman will allow customers to leverage existing and future opportunities to
- Intel AI-Powered Backpack Helps Visually Impaired Navigate Worldhttps://modernod.com/news/intel-ai-powered-backpack-helps-visually-impaired-navigate-world/2479014/Artificial intelligence (AI) developer Jagadish K. Mahendran and his team designed an AI-powered, voice-activated backpack that can help the visually impaired navigate and perceive the world around them. The backpack helps detect common challenges such as traffic signs, hanging obstacles, crosswa
- Jasmine Pachnanda Named Senior Vice President for CEO Leadership Alliance; Will Lead SoCal AI Initiativehttps://modernod.com/news/jasmine-pachnanda-named-senior-vice-president-for-ceo-leadership-alliance-will-lead-socal-ai-initiative/2479012/The CEO Leadership Alliance – Orange County (CLA-OC) has named Jasmine Pachnanda as Senior Vice President. Ms. Pachnanda will work with a range of partners and stakeholders, harnessing efforts to grow and demonstrate Southern California’s emerging leadership as a worldwide center for
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Productshttps://modernod.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan. “We’re very excited to work with Wak
- AdHawk Microsystems Launches AdHawk MindLink Eye Tracking Researchhttps://modernod.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/AdHawk Microsystems announced the launch of AdHawk MindLink wearable eye tracking system. AdHawk MindLink produces accurate eye movement data to provide deep insights into human behavior, ocular, and neurological health. Delivered in the form of lightweight and comfortable glasses, the AdHawk sys
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- Nidek Launches RT-6100 CB for Windows to Enhance Refraction Workflowhttps://modernod.com/news/nidek-launches-rt-6100-cb-for-windows-to-enhance-refraction-workflow/2478994/Nidek has announced the launch of RT-6100 CB for Windows, an optional control software for the RT-6100 Intelligent Refractor and the TS-610 Tabletop Refraction System. As the environment is shifting and the dem
- AstraZeneca’s COVID-19 Vaccine Shows 79% Efficacy in Pivotal US Studyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-shows-79-efficacy-in-pivotal-us-study/2478995/AstraZeneca on Monday announced that its vaccine AZD1222 demonstrated efficacy of 79% at preventing symptomatic COVID-19 in a late-stage study conducted in the US. Results also showed that the vaccine had 100% efficacy at preventing severe disease and hospitalization, with comparable effectivenes